[18F]F-DED PET Imaging of Reactive Astrocytes in Multiple Sclerosis (F-DED PET MS)
[18F] Fluorodeprenyl-D2 PET Imaging of Reactive Astrocytes as Chronic Active Inflammation Marker in Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Aida Giraldo, MD
- Phone Number: 933160675
- Email: agiraldo@researchmar.net
Study Locations
-
-
-
Barcelona, Spain, 08003
- Hospital del Mar Research Institute
-
Contact:
- Silvia Susin, MD
- Phone Number: 933160675
- Email: ssusin@researchmar.net
-
Contact:
- Silvia Susin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-65 years.
- Confirmed diagnosis of multiple sclerosis according to the 2017 McDonald criteria.
- Ability to undergo MRI and PET imaging.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: [18F]F-DED PET
Participants with multiple sclerosis will receive a single intravenous administration of [18F]fluorodeprenyl-D2 ([18F]F-DED; 200 ± 25 MBq) followed by PET/CT imaging.
MRI will be performed within one week of the PET/CT scan.
Participants will undergo longitudinal clinical follow-up for 3 years.
|
Participants will receive a single intravenous administration of [18F]fluorodeprenyl-D2 ([18F]F-DED) at a dose of 200 ± 25 MBq, followed by PET/CT imaging to assess reactive astrocytes in multiple sclerosis lesions.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Accuracy of [18F]F-DED PET for Detecting Chronic Active Lesions
Time Frame: Baseline (PET/CT and MRI performed within 1 week)
|
Diagnostic accuracy of [18F]F-DED PET imaging for identifying chronic active lesions in patients with multiple sclerosis, using MRI-detected paramagnetic rim lesions (PRLs) as the reference standard.
Diagnostic performance will be assessed by area under the receiver operating characteristic curve (AUC-ROC), sensitivity, and specificity.
|
Baseline (PET/CT and MRI performed within 1 week)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025/12341/I
- 2025 (U.S. NIH Grant/Contract: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2026-525702-35-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.